PR Newswire·Nov 12, 2026, 4:30 PM ET

Aethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate Update

Aethlon Medical reported fiscal second quarter results ended September 30, 2026, alongside a corporate update on its merger plans.
On September 17, 2026, the company signed a merger agreement with North Immunology to form a combined entity operating under the name North Immunology, Inc.
Workforce reductions were implemented near the end of the quarter, retaining key staff for regulatory duties and the Australian oncology trial while planning to wind down legacy activities upon merger closing.
Aethlon shareholders are expected to receive contingent value rights (CVRs) to potentially benefit from future monetization of the legacy Hemopurifier business, though no payment is guaranteed.
The Phase 1 oncology clinical trial in Australia treated eight patients across three cohorts, with recruitment intended to conclude soon due to the limited window before the merger.
Cash and cash equivalents totaled approximately $6.5 million as of September 30, 2026.
Consolidated operating expenses rose 77.2% to $2.7 million for the quarter, driven by higher professional fees related to the merger.
The company holds FDA Breakthrough Device Designation for the Hemopurifier to treat advanced cancer unresponsive to standard care and life-threatening viruses.
The merger agreement notes that completion is not assured regarding timing, terms, or final execution.